A novel human anti-syndecan-1 antibody inhibits vascular maturation and tumour growth in melanoma

European Journal of Cancer

Volumn 49, Issue 8, 2013, Pages 2022-2033

  Orecchia, Paola ^a   Conte, Romana ^a   Balza, Enrica ^a   Petretto, Andrea ^b   Mauri, Pierluigi ^c   Mingari, Maria Cristina ^a,d   Carnemolla, Barbara ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b G GASLINI INSTITUTE   (Italy)

^c INSTITUTE OF BIOMEDICAL TECHNOLOGIES   (Italy)

^d UNIVERSITY OF GENOA   (Italy)

Author keywords

Angiogenesis; CD138; Human recombinant antibody; Melanoma; Ovarian carcinoma; Syndecan 1; Tumour growth; Vascular mimicry; VEGFR2

Indexed keywords

RECOMBINANT ANTIBODY; RECOMBINANT ANTIBODY OC 46F2; SYNDECAN 1; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN SPECIFICITY; ARTICLE; CANCER INHIBITION; DRUG EFFICACY; DRUG SCREENING; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; MAMMAL CELL; MASS SPECTROMETRY; MELANOMA; MELANOMA CELL; MOLECULARLY TARGETED THERAPY; NONHUMAN; OVARY CARCINOMA; PHAGE DISPLAY; PRIORITY JOURNAL; TUMOR MICROENVIRONMENT;

AMINO ACID SEQUENCE; ANIMALS; CELL LINE, TUMOR; CERCOPITHECUS AETHIOPS; CHO CELLS; COS CELLS; CRICETINAE; CRICETULUS; FEMALE; HEK293 CELLS; HUMANS; MELANOMA; MICE; MICE, INBRED NOD; MICE, SCID; MOLECULAR SEQUENCE DATA; NEOVASCULARIZATION, PATHOLOGIC; OVARIAN NEOPLASMS; PEPTIDE LIBRARY; RECOMBINANT PROTEINS; SINGLE-CHAIN ANTIBODIES; SYNDECAN-1; TUMOR BURDEN; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84876683956     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2012.12.019     Document Type: Article

References (43)

1. I. Pacheco, C. Buzea, and V. Tron Towards new therapeutic approaches for malignant melanoma Expert Rev Mol Med 13 2011 e33
2. C. Robert, L. Thomas, and I. Bondarenko Ipilimumab plus dacarbazine for previously untreated metastatic melanoma N Engl J Med 364 2011 2517 2526
3. P.B. Chapman, A. Hauschild, and C. Robert Improved survival with vemurafenib in melanoma with BRAF V600E mutation N Engl J Med 364 2011 2507 2516
4. C. Schuster, H.P. Eikesdal, and H. Puntervoll Clinical efficacy and safety of bevacizumab monotherapy in patients with metastatic melanoma: predictive importance of induced early hypertension PLoS One 7 2012 e38364
5. V.P. Grignol, T. Olencki, and K. Relekar A phase 2 trial of bevacizumab and high-dose interferon alpha 2B in metastatic melanoma J Immunother 34 2011 509 515
6. P.P. Vihinen, M. Hernberg, and M.S. Vuoristo A phase II trial of bevacizumab with dacarbazine and daily low-dose interferon-alpha2a as first line treatment in metastatic melanoma Melanoma Res 20 2010 318 325
7. M. Del Vecchio, R. Mortarini, and S. Canova Bevacizumab plus fotemustine as first-line treatment in metastatic melanoma patients: clinical activity and modulation of angiogenesis and lymphangiogenesis factors Clin Cancer Res 16 2010 5862 5872
8. P.G. Corrie, B. Basu, and K.A. Zaki Targeting angiogenesis in melanoma: prospects for the future Ther Adv Med Oncol 2 2010 367 380
9. K.B. Kim, J.A. Sosman, and J.P. Fruehauf BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma J Clin Oncol 30 2012 34 41
10. N. Pasche, and D. Neri Immunocytokines: a novel class of potent armed antibodies Drug Discov Today 17 2012 583 590
11. M. Kaspar, L. Zardi, and D. Neri Fibronectin as target for tumour therapy Int J Cancer 118 2006 1331 1339
12. D. Neri, and R. Bicknell Tumour vascular targeting Nat Rev Cancer 5 2005 436 446
13. T.K. Eigentler, B. Weide, and F. de Braud A dose-escalation and signal-generating study of the immunocytokine L19-IL2 in combination with dacarbazine for the therapy of patients with metastatic melanoma Clin Cancer Res 17 2011 7732 7742
14. B.M. Edwards, S.C. Barash, and S.H. Main The remarkable flexibility of the human antibody repertoire; isolation of over one thousand different antibodies to a single protein, BLyS J Mol Biol 334 2003 103 118
15. A.R. Bradbury, S. Sidhu, S. Dübel, and J. McCafferty Beyond natural antibodies: the power of in vitro display technologies Nat Biotechnol 29 2011 245 254
16. B. Carnemolla, A. Leprini, G. Allemanni, M. Saginati, and L. Zardi The inclusion of the type III repeat ED-B in the fibronectin molecule generates conformational modifications that unmask a cryptic sequence J Biol Chem 267 1992 24689 24692
17. V. Vogel Mechanotransduction involving multimodular proteins: converting force into biochemical signals Annu Rev Biophys Biomol Struct 35 2006 459 488
18. X. Xian, S. Gopal, and J.R. Couchman Syndecans as receptors and organizers of the extracellular matrix Cell Tissue Res 339 2010 31 46
19. Y.H. Teng, R.S. Aquino, and P.W. Park Molecular functions of syndecan-1 in disease Matrix Biol 31 2012 3 16
20. V.C. Ramani, P.S. Pruett, C.A. Thompson, L.D. Delucas, and R.D. Sanderson Heparan sulfate chains of syndecan-1 regulate ectodomain shedding J Biol Chem 287 2012 9952 9961
21. Y. Yang, V. Macleod, and H.Q. Miao Heparanase enhances syndecan-1 shedding: a novel mechanism for stimulation of tumour growth and metastasis J Biol Chem 282 2007 13326 13333
22. D.M. Beauvais, B.J. Ell, A.R. McWhorter, and A.C. Rapraeger Syndecan-1 regulates alphavbeta3 and alphavbeta5 integrin activation during angiogenesis and is blocked by synstatin, a novel peptide inhibitor J Exp Med 206 2009 691 705
23. A. Purushothaman, L. Chen, and Y. Yang Heparanase stimulation of protease expression implicates it as a master regulator of the aggressive tumor phenotype in myeloma J Biol Chem 283 2008 32628 32636
24. T. Manon-Jensen, Y. Itoh, and J.R. Couchman Proteoglycans in health and disease: the multiple roles of syndecan shedding FEBS J 277 2010 3876 3889
25. A. Purushothaman, T. Uyama, and F. Kobayashi Heparanase-enhanced shedding of syndecan-1 by myeloma cells promotes endothelial invasion and angiogenesis Blood 115 2010 2449 2457
26. J. Reiland, R.D. Sanderson, and M. Waguespack Heparanase degrades syndecan-1 and perlecan heparan sulfate: functional implications for tumour cell invasion J Biol Chem 279 2004 8047 8055
27. M.P. O'Connell, J.L. Fiori, and E.K. Kershner Heparan sulfate proteoglycan modulation of Wnt5A signal transduction in metastatic melanoma cells J Biol Chem 284 2009 28704 28712
28. G. Pietra, C. Manzini, and M. Vitale Natural killer cells kill human melanoma cells with characteristics of cancer stem cells Int Immunol 21 2009 793 801
29. M. Silacci, S. Brack, and G. Schirru Design, construction, and characterization of a large synthetic human antibody phage display library Proteomics 9 2005 2340 2350
30. L. Giovannoni, F. Viti, L. Zardi, and D. Neri Isolation of anti-angiogenesis antibodies from a large combinatorial repertoire by colony filter screening Nucleic Acids Res 29 2001 E27
31. B. Carnemolla, L. Borsi, and E. Balza Enhancement of the antitumour properties of interleukin-2 by its targeted delivery to the tumour blood vessel extracellular matrix Blood 99 2002 1659 1665
32. P. Orecchia, R. Conte, and E. Balza Identification of a novel cell binding site of periostin involved in tumour growth Eur J Cancer 47 2011 2221 2229
33. S.C. Williams, and G. Winter Cloning and sequencing of human immunoglobulin V lambda gene segments Eur J Immunol 23 1993 1456 1461
34. J. Reiland, R.D. Sanderson, and M. Waguespack Heparanase degrades syndecan-1 and perlecan heparan sulfate: functional implications for tumor cell invasion J Biol Chem 279 2004 8047 8055
35. I. Helfrich, I. Scheffrahn, and S. Bartling Resistance to antiangiogenic therapy is directed by vascular phenotype, vessel stabilization, and maturation in malignant melanoma J Exp Med 207 2010 491 503
36. R.V. Iozzo, and R.D. Sanderson Proteoglycans in cancer biology, tumour microenvironment and angiogenesis J Cell Mol Med 15 2011 1013 1031
37. S. Tugues, S. Koch, L. Gualandi, X. Li, and L. Claesson-Welsh Vascular endothelial growth factors and receptors: anti-angiogenic therapy in the treatment of cancer Mol Aspects Med 32 2011 88 111
38. S. Lamorte, S. Ferrero, and S. Aschero Syndecan-1 promotes the angiogenic phenotype of multiple myeloma endothelial cells Leukemia 26 2012 1081 1090
39. M.J. Hendrix, E.A. Seftor, A.R. Hess, and R.E. Seftor Vasculogenic mimicry and tumour-cell plasticity: lessons from melanoma Nat Rev Cancer 3 2003 411 421
40. S.M. Weis, and D.A. Cheresh Tumour angiogenesis: molecular pathways and therapeutic targets Nat Med 17 2011 1359 1370
41. R.K. Jain, D.G. Duda, and C.G. Willett Biomarkers of response and resistance to antiangiogenic therapy Nat Rev Clin Oncol 6 2009 327 338
42. R.K. Jain, and P. Carmeliet SnapShot: tumour angiogenesis Cell 149 2012 1408
43. C. Rousseau, L. Ferrer, and S. Supiot Dosimetry results suggest feasibility of radioimmunotherapy using anti-CD138 (B-B4) antibody in multiple myeloma patients Tumour Biol 33 2012 679 688